Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Position Boosted by Quest Partners LLC

Quest Partners LLC raised its holdings in shares of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) by 65.0% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 19,123 shares of the biotechnology company’s stock after acquiring an additional 7,535 shares during the period. Quest Partners LLC’s holdings in Enanta Pharmaceuticals were worth $198,000 as of its most recent SEC filing.

Other institutional investors also recently added to or reduced their stakes in the company. Allspring Global Investments Holdings LLC acquired a new position in shares of Enanta Pharmaceuticals during the second quarter valued at $35,000. US Bancorp DE grew its position in Enanta Pharmaceuticals by 4,933.7% in the 3rd quarter. US Bancorp DE now owns 4,329 shares of the biotechnology company’s stock valued at $45,000 after buying an additional 4,243 shares in the last quarter. State Board of Administration of Florida Retirement System acquired a new position in Enanta Pharmaceuticals during the 1st quarter valued at about $118,000. Virtu Financial LLC acquired a new position in Enanta Pharmaceuticals during the 1st quarter valued at about $191,000. Finally, American Century Companies Inc. raised its position in shares of Enanta Pharmaceuticals by 35.4% during the 2nd quarter. American Century Companies Inc. now owns 27,892 shares of the biotechnology company’s stock worth $362,000 after buying an additional 7,287 shares in the last quarter. Institutional investors and hedge funds own 94.99% of the company’s stock.

Analysts Set New Price Targets

ENTA has been the topic of a number of research analyst reports. JPMorgan Chase & Co. lowered their price objective on shares of Enanta Pharmaceuticals from $11.00 to $10.00 and set an “underweight” rating on the stock in a research note on Tuesday, August 6th. JMP Securities reaffirmed a “market outperform” rating and set a $21.00 price target (down from $22.00) on shares of Enanta Pharmaceuticals in a research note on Tuesday. Evercore ISI raised Enanta Pharmaceuticals to a “strong-buy” rating in a research note on Tuesday, August 6th. HC Wainwright reaffirmed a “buy” rating and set a $27.00 target price on shares of Enanta Pharmaceuticals in a research note on Thursday, October 10th. Finally, Robert W. Baird dropped their price target on shares of Enanta Pharmaceuticals from $26.00 to $20.00 and set an “outperform” rating on the stock in a research report on Tuesday. One investment analyst has rated the stock with a sell rating, one has issued a hold rating, three have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $19.50.

Enanta Pharmaceuticals Stock Performance

Shares of NASDAQ:ENTA opened at $8.83 on Thursday. The company has a market capitalization of $187.11 million, a PE ratio of -1.61 and a beta of 0.56. The stock has a fifty day moving average of $10.92 and a 200-day moving average of $12.30. Enanta Pharmaceuticals, Inc. has a one year low of $8.00 and a one year high of $17.80.

Enanta Pharmaceuticals Company Profile

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.